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Statins have multiple effects, including anti-inflammatory
actions, lowering C-reactive protein levels, and reducing
coronary events. We performed a post hoc analysis of the
randomized placebo-controlled 4D Study that had evaluated
the efficacy and safety of atorvastatin in 1255 patients with
type 2 diabetes mellitus who were on maintenance
hemodialysis. Here we determined the relationship between
atorvastatin treatment, C-reactive protein, and the outcome
of patients who had pre-specified and adjudicated endpoints
of all-cause mortality, composite vascular endpoint,
myocardial infarction, sudden death, and stroke. Atorvastatin
had no significant effect on the risk of composite vascular
endpoint or death relative to placebo in any quartile of
baseline C-reactive protein. These baseline levels were not
significantly different between the treated and placebo
group and remained stable at 6 months on atorvastatin but
significantly increased in those patients on placebo. All of the
patients with baseline C-reactive protein in the fourth
quartile had a significantly increased risk of deaths and in
composite vascular endpoint compared to patients in the
first quartile. The mean value of two consecutive C-reactive
protein measurements was associated with significant
increases in the risk of sudden death, stroke, all-cause
mortality and composite vascular endpoint. Our results show
that C-reactive protein was highly predictive of outcome, but
atorvastatin treatment was not associated with reduced
relative risks in the composite vascular endpoint or mortality
in patients on hemodialysis with or without inflammation.
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To improve vascular risk stratification in dialysis patients
regular assessment of high-sensitivity C-reactive protein
(CRP) is recommended.1 This recommendation has been
issued despite a lack of specific antiinflammatory treatment
strategies that could result from such screening. Studies in
stable patients with coronary heart disease and normal
kidney function as well as in patients with acute coronary
syndromes have raised the possibility that the clinical benefit
of statins are related to their antiinflammatory effect.2,3
Statins have been shown to lower CRP in a variety of patient
populations.4,5 This raises the question whether a statin
would be an especially effective cardiovascular event-lowering
drug in hemodialysis patients depending on the degree of
inflammation as indicated by baseline CRP. More than 20 out
of 100 diabetic hemodialysis patients die per year6 and
identifying treatments that decrease inflammation and high
CRP may translate into a significant reduction of cardiovas-
cular events.7
We performed a post hoc analysis of the 4D study (German
Diabetes Dialysis Study—Die Deutsche Diabetes Dialyse
Studie),8 which evaluated the efficacy and safety of
atorvastatin in 1255 patients with type 2 diabetes mellitus
on maintenance hemodialysis treatment. The purpose of this
study was to evaluate (1) the effect of atorvastatin treatment
on CRP serum concentrations,5 (2) the relationship between
baseline CRP and cardiovascular endpoints (for example
sudden death, myocardial infarction, and stroke), (3) the
relationship between changes of CRP upon follow-up and
cardiovascular events, and (4) the effect of atorvastatin on
cardiovascular endpoints in subgroups stratified according to
CRP at baseline.
RESULTS
Of 1255 patients, 1249 had a baseline, 1204 had a post-
baseline, and 1202 had the two CRP measurements. Results
from 633 patients on placebo and 616 patients on
atorvastatin at baseline and 605 on placebo and 599 on
atorvastatin after a median of 182 days (interquartile range
177–185 days, referred here as 6 months) were available for
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analysis. The mean follow-up periods were 3.96 years
(median 4.0 years) and 3.91 years (median 4.08 years) in
patients receiving atorvastatin or placebo, respectively.
During follow-up, 465 patients reached the composite
vascular endpoint (CVE, cardiac death, nonfatal myocardial
infarction, and stroke). Fatal and nonfatal myocardial
infarction, and stroke occurred in 200 and 99 patients,
respectively. Overall 612 patients died, of whom 160 died of
sudden death.
The characteristics of study participants grouped accord-
ing to baseline CRP are shown in Table 1.
Effect of atorvastatin on CRP
Median baseline CRP was high (overall median: 5.0 mg/l) and
did not differ significantly between groups (P¼ 0.170;
placebo group: quartile 1, 2.5 mg/l; median, 5.5 mg/l; mean:
10.99±17.7 mg/l; quartile 3, 12.4 mg/l; atorvastatin group:
quartile 1, 2.2 mg/l; median, 4.6 mg/l; mean 10.91±20.4 mg/
l; quartile 3, 12.45 mg/l).
During treatment with atorvastatin CRP remained stable
(P¼ 0.706) (change from baseline: quartile 1, 3.1 mg/l;
median, 0.2 mg/l; quartile 3, 2.9 mg/l) whereas it increased
during placebo treatment (P¼ 0.001; change from baseline:
quartile 1, 2.7 mg/l; median, 0.4 mg/l; quartile 3, 4.9 mg/l).
Therefore, post-baseline CRP was lower (P¼ 0.002) in
atorvastatin-treated (median, 4.4 mg/l) compared to place-
bo-treated patients (median, 6.0 mg/l) as was the change
from baseline (P¼ 0.012). The distribution of CRP at
baseline and at follow-up is shown in Figure 1.
Baseline CRP and the risk of sudden death, stroke,
myocardial infarction, composite vascular endpoint, and all-
cause mortality
The risk of experiencing a CVE and of dying from any cause
increased by 10 and 25%, respectively, per unit increase in
log-transformed CRP (hazard ratio (HR): 1.10; 95%
confidence interval (CI): 1.01–1.18; P¼ 0.023; HR: 1.25;
95% CI: 1.17–1.33; Po0.001, respectively). One unit increase
in logarithmically transformed CRP was equal to a 2.72-fold
increase in absolute values. No statistically significant
association between baseline CRP and single components of
the CVE was detected (risk of sudden death—HR: 1.13; 95%
CI: 1.00–1.29; P¼ 0.060; stroke—HR: 1.11; 95% CI:
0.94–1.32; P¼ 0.233; myocardial infarction—HR: 1.12; 95%
CI: 1.00–1.26; P¼ 0.056). Results of analyses with quartiles of
baseline CRP are shown in Figure 2a and b, and Table 2.
Table 1 | Baseline patient characteristics according to quartiles of baseline CRP (p2.3, 42.3 to 5, 45 to 12.4, and 412.4 mg/l)
CRP
Quartile 1 p2.3 mg/l
n=316
Quartile 2 42.3 to
p5 mg/l n=310
Quartile 3 45 to
p12.4 mg/l n=312
Quartile 4 412.4 mg/l
n=311 P-value
Age (years) 66.4±8.1 65.6±8.2 65.9±8.1 64.8±8.6 0.270
Gender (male/female) 155/161 177/133 160/152 180/131 0.169
Ever smoking (% (n)) 36 (114) 40 (123) 38 (119) 48 (149) 0.089
Body mass index (kg/m2) 26.6±4.5 27.5±4.7 28.1±5.1 28.0±4.9 o0.001
Systolic blood pressure (mm Hg) 146±23 148±22 145±21 143±21 0.012
Diastolic blood pressure (mm Hg) 76±11 77±11 75±11 75±11 0.139
Ultrafiltration volumea (kg) 2.21±1.17 2.12±1.12 2.30±1.19 2.38±1.30 0.066
Arteriovenous fistula (% (n)) 95 (301) 95 (294) 93 (288) 90 (281) 0.029
Time receiving dialysis (months) 8.2±6.6 8.1±6.8 8.3±7.1 8.4±7.1 0.972
History of b
Arrhythmia (% (n)) 17 (53) 17 (54) 18 (56) 23 (71) 0.088
Myocardial infarction, CABGc, PCId,
or CHDe (% (n))
30 (96) 30 (93) 26 (81) 31 (95) 0.564
Congestive heart failuref (% (n)) 31 (97) 36 (111) 36 (113) 39 (120) 0.088
Stroke or TIAg (% (n)) 16 (52) 18 (56) 19 (58) 18 (56) 0.902
Peripheral vascular disease (% (n)) 39 (122) 42 (130) 46 (142) 52 (161) 0.010
Hemoglobin (g/100 ml) 11.0±1.3 11.1±1.4 10.9±1.3 10.6±1.3 o0.001
HbA1ch (%) 6.57±1.21 6.68±1.29 6.74±1.19 6.90±1.32 0.011
Phosphate (mg/l) 6.06±1.56 5.91±1.52 5.95±1.57 6.21±1.77 0.127
Albumin (g/100 ml) 3.89±0.28 3.87±0.27 3.80±0.31 3.72±0.32 o0.001
LDL cholesterol (mg/100 ml) 126±28 128±31 126±29 122±31 0.057
CRP (mg/l) (median (25th and 75th percentile)) 1.3 (0.9–1.7) 3.5 (2.9–4.2) 7.5 (6.1–9.6) 22.8 (16–34.9) —
P-values for comparison between groups of patients according to baseline CRP quartiles were derived from a general linear model for continuous variables or logistic
regression for categorical variables both adjusted for age and gender, as appropriate.
Data are given as mean±standard deviation. To convert hemoglobin values to millimoles per liter, multiply by 0.62. To convert values for phosphate to millimoles per liter,
multiply by 0.32. To convert values for LDL cholesterol to millimoles per liter, multiply by 0.03.
aThe ultrafiltration volume was calculated based on the body weight before and after dialysis at the randomization visit.
bTypes of disease and intervention are not mutually exclusive.
cCoronary artery bypass grafting surgery.
dPercutaneous coronary intervention.
eCoronary heart disease, documented by coronary angiography.
fPredominantly New York Heart Association II.
gTransient ischemic attack.
hGlycated hemoglobin.
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Mean and change from baseline CRP and outcome
Although a statistically significant association between base-
line CRP and sudden death or stroke was slightly missed, the
mean value resulting from two consecutive measurements
was predictive of sudden death (HR: 1.20; 95% CI: 1.05–1.37,
P¼ 0.007) and stroke (HR: 1.20; 95% CI: 1.01–1.42;
P¼ 0.042) with a 20% increase in relative risk per unit
increase in log-transformed mean CRP. In accordance with
the baseline measurement, the mean of two CRP measure-
ments was also predictive of the CVE (HR: 1.10; 95% CI:
1.02–1.20; P¼ 0.018) and death due to any cause (HR: 1.30;
95% CI: 1.21–1.39; Po0.001). However, mean CRP was not
associated with myocardial infarction (HR: 1.07; 95% CI:
0.95–1.20; P¼ 0.303).
In a second step, the change from baseline CRP was
investigated. Patients were divided into four groups accord-
ing to quartiles of percent change from baseline CRP
(p47.3%, X47.3 up to 3.6%, 43.6 up to 100%, and
4100%).
The relative risk of sudden death was lowest in patients
with a decrease of CRP X47.3% (quartile 2 versus 1—HR:
1.80; 95% CI: 1.10–2.97; P¼ 0.021; quartile 3 versus 1—HR:
1.86; 95% CI: 1.14–3.04; P¼ 0.013; quartile 4 versus 1: HR—
1.67; 95% CI: 1.02–2.75; P¼ 0.042). No significant associa-
tion between the change in CRP (continuous and categorical
variable) and the risk of stroke, myocardial infarction, CVE,
and all-cause death was observed.
Effect of atorvastatin on the composite vascular endpoint
and on mortality
There was no statistically significant effect of atorvastatin
treatment on the adjusted relative risk of the CVE or on all-
cause death in patients grouped according to quartiles of
baseline CRP (Table 3).
Intriguingly, the HR for the two endpoints was lowest in
the second and third quartile. Driven by these data, we
looked at the effect of atorvastatin on the CVE and all-cause
death in patients with CRP concentrations 42.3 and
p12.4 mg/l (second and third quartile combined) and found
a significant effect of atorvastatin on all-cause death (HR:
0.78; 95% CI: 0.62–0.99; P¼ 0.038) whereas no significant
influence on the CVE (HR: 0.85; 95% CI: 0.65–1.10;
P¼ 0.210) was detected.
DISCUSSION
A randomized, placebo-controlled trial of atorvastatin
(20 mg/day) in 1255 patients with type 2 diabetes mellitus
on hemodialysis treatment who experienced a high incidence
of prespecified and centrally adjudicated endpoints was the
basis of the present analysis.
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Figure 1 | CRP concentrations according to treatment group at
baseline and after a mean follow-up time of 167±66 days on
atorvastatin or placebo treatment. This diagram is restricted to
CRP concentrations within the 10th and 90th percentile to assure
its readability (maximum CRP concentration 328 mg/l). Median
baseline CRP did not differ significantly between groups
(P¼ 0.170). During treatment with atorvastatin CRP remained
stable (P¼ 0.706) whereas it increased during placebo treatment
(P¼ 0.001). Median post-baseline CRP was lower (P¼ 0.002) in
atorvastatin treated compared to placebo-treated patients as was
the change from baseline (P¼ 0.012).
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Figure 2 | Estimated cumulative incidences of all-cause death and the composite vascular endpoint. (a, b) Kaplan–Meier estimates for
time to all-cause death (a), composite vascular endpoint (cardiac death, nonfatal myocardial infarction, and stroke) (b) in subgroups of
patients according to quartiles of baseline CRP (quartile 1: CRP p2.3 mg/l, quartile 2: CRP 42.3 to p5 mg/l, quartile 3: CRP 45 to
p12.4 mg/l, quartile 4: CRP 412.4 mg/l).
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The results show that CRP was highly predictive of
outcome but atorvastatin treatment was not associated with a
reduction in the relative risk of the CVE or mortality in either
inflamed or noninflamed patients. Surprisingly, CRP in-
creased significantly on placebo but remained stable on
atorvastatin therapy, thus displaying overall antiinflamma-
tory potency. The mean value resulting of the baseline
measurement and a second CRP measurement, 6 months
apart, demonstrated the predictive value of CRP for sudden
death and stroke.
In the general population the risk reduction attributable
to statin therapy was substantially greater among subjects
with evidence of inflammation than among those with-
out.9–11 This clear relationship was not retrieved within the
present study. Results from analyses of patients grouped
within the first, second, third, and fourth quartile of baseline
CRP suggested a J-shaped distribution of adjusted HRs of all-
cause death and the CVE associated with atorvastatin
treatment. It seems that atorvastatin was more effective in
patients with CRP serum concentrations in the intermediate
range (quartiles 2 and 3).
One might argue that uremia or the hemodialysis
procedure per se are causing a different inflammatory state
which corresponds to approximately 5- to 10-fold higher
CRP concentrations than in the general population.12 This
more pronounced and progressive inflammatory state results
Table 2 | Risk of all-cause death, composite vascular endpoint, sudden death, stroke, and myocardial infarction by quartiles of
baseline CRP
CRP
Quartile 1 p2.3 mg/l
n=316
Quartile 2 42.3 to p5 mg/l
n=310
Quartile 3 45 to p12.4 mg/l
n=312
Quartile 4 412.4 mg/l
n=311
All-cause death
Number of events during study (n) 119 144 157 192
Kaplan–Meier estimatea (95%
confidence interval)
0.38 (0.32–0.44) 0.46 (0.40–0.53) 0.52 (0.46–0.59) 0.62 (0.56–0.69)
Adjusted hazard ratiob
(95% confidence interval)
c 1.34 (1.05–1.72) 1.55 (1.21–1.97) 2.04 (1.60–2.59)
P=0.019 Po0.001 Po0.001
Composite vascular endpointd
Number of events during study (n) 110 106 130 119
Kaplan–Meier estimatea (95%
confidence interval)
0.37 (0.31–0.43) 0.39 (0.32–0.45) 0.50 (0.43–0.57) 0.48 (0.40–0.55)
Adjusted hazard ratiob
(95% confidence interval)
c 1.10 (0.84–1.44) 1.41 (1.09–1.83) 1.32 (1.00–1.73)
P=0.498 P=0.009 P=0.047
Sudden death
Number of events during study (n) 41 27 47 45
Kaplan–Meier estimatea (95%
confidence interval)
0.15 (0.11–0.20) 0.11 (0.07–0.16) 0.20 (0.14–0.26) 0.19 (0.13–0.24)
Adjusted hazard ratiob (95%
confidence interval)
c 0.76 (0.46–1.24) 1.35 (0.88–2.07) 1.40 (0.90–2.17)
P=0.270 P=0.174 P=0.135
Stroke
Number of events during study (n) 23 25 29 22
Kaplan–Meier estimatea
(95% confidence interval)
0.08 (0.05–0.12) 0.11 (0.06–0.15) 0.13 (0.08–0.18) 0.09 (0.05–0.12)
Adjusted hazard ratiob
(95% confidence interval)
c 1.32 (0.75–2.34) 1.61 (0.92–2.79) 1.41 (0.78–2.56)
P=0.339 P=0.093 P=0.256
Myocardial infarction
Number of events during study (n) 43 51 61 45
Kaplan–Meier estimatea
(95% confidence interval)
0.18 (0.12–0.23) 0.20 (0.15–0.26) 0.28 (0.21–0.35) 0.23 (0.16–0.31)
Adjusted hazard ratiob
(95% confidence interval)
c 1.32 (0.88–1.99) 1.66 (1.12–2.46) 1.29 (0.84–1.98)
P=0.186 P=0.012 P=0.242
CRP, C-reactive protein.
aUnadjusted Kaplan–Meier estimates at end of year 4.
bExplanatory variables were selected by a stepwise process with adjustment for: gender, age, atorvastatin treatment, phosphate, hemoglobin, glycated hemoglobin, LDL
cholesterol, ever smoking, systolic and diastolic blood pressure, body mass index, ultrafiltration volume, duration of dialysis, arteriovenous fistula, history of stroke or
transitory ischemic attack, coronary artery disease (history of myocardial infarction, coronary artery bypass grafting, percutaneous coronary intervention, and angiographically
documented coronary artery disease), history of peripheral vascular disease, and history of congestive heart failure (predominantly New York Heart Association class II).
cThe group of patients with baseline CRP levels within the first quartile served as reference for each of the other three quartiles.
dComposite vascular endpoint consists of myocardial infarction, cardiac death and stroke.
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from intermediate stimulation by the exposure of blood to
dialysate or to dialysis membranes themselves. Against this
background, it is unclear whether an even higher dose of
atorvastatin (that is 80 mg/day) with a more potent
antiinflammatory effect would have been sufficient to
translate into a significant reduction of events or mortality
and to control high CRP from various sources.11,13 Apart
from the inflammation hypothesis, it could also be argued
that the currently recommended therapeutic target of a low-
density lipoprotein (LDL) cholesterol of 70 mg/100 ml for
patients at very high risk of coronary artery disease has
already been achieved in the 4D Study.8 Recently, age has
been proposed to be a limiting factor for risk stratification or
predicting response to statin therapy in elderly people,14 a
phenomenon that has also been described for other risk
factors such as cholesterol.15 However the patients in the
pravastatin in the elderly at risk (PROSPER) study14 still were
9 years older, than the patients with type 2 diabetes mellitus
in the 4D trial (median 66 years).
The finding of a nonsignificant 4% decrease of CRP in the
atorvastatin group is at first glance in line with the findings of
the original 4D study 9. However, CRP increased unexpect-
edly in the placebo group. Taken this into account, the overall
reduction in CRP was 27% on atorvastatin which is quite
similar to 28% in a recent meta-analysis including 23 trials of
lipid-lowering therapy.4,16 Thus against first glance, the
known antiinflammatory effects of statins were actually
retrieved in the present study. Most trials show stable serum
CRP concentrations over time.16–21 Only in survivors of
myocardial infarction (cholesterol and recurrent events
study) CRP tended to increase over the follow-up period of
5 years.22 This effect in the cholesterol and recurrent events
study was less pronounced than in the present study in which
a significant difference between atorvastatin and placebo
treated patients was detected within 6 months of treatment.
We suggest that the increase in CRP in the placebo group is
pointing towards an ongoing progressive inflammatory state.
Known causative factors are multiple and need to be
elucidated further. In that respect, one may also take a more
detailed look at the large group of patients suffering from
peripheral vascular disease at study entry. Peripheral vascular
disease was the major cause of hospitalization (34%) during
follow-up and the diabetic foot syndrome may have
contributed to the increase in CRP over time.14 It is tempting
to speculate that the raising serum CRP concentration is the
result of contamination due to infection or sepsis. Even
though, we should have seen a beneficial effect of atorvastatin
treatment on cardiovascular events and outcome. Recent
observational data from the Choices for Healthy Outcomes in
Caring study for ESRD demonstrated a strong and indepen-
dent association between statin treatment and the reduction
in hospitalizations because of sepsis in hemodialysis
patients.23 Taken together, we believe that the microinflam-
matory state in subjects with normal kidney function cannot
be compared with that in the population of hemodialysis
patients.
Despite the large body of epidemiological data relating to
CRP, few studies examined the relationship between long-
itudinal changes in CRP and prognosis.24 In contrast to a
study in the United Kingdom that followed hospital inpatient
admissions,24 we did not find an association between the
change in CRP and cardiovascular events or all-cause death.
As both studies had a similar follow-up and included a large
number of events, the varying results may mainly be
attributed to different patient characteristics and a different
definition of change in CRP.
Table 3 | Adjusted hazard ratios of all-cause death and the composite vascular endpoint associated with atorvastatin
treatment in subgroups of patients within the first, second, third, and fourth quartile of baseline CRP
Number of events
Adjusted hazard ratioa
(atorvastatin/placebo)
Active Placebo (95% Confidence interval) P-value
CRP quartile 1: p2.3 mg/l, n=316
All-cause death 64 55 1.07 (0.74–1.55) 0.707
Composite vascular endpointb 60 50 1.19 (0.81–1.76) 0.376
CRP Quartile 2: 42.3 and p5 mg/l, n=310
All-cause death 67 77 0.73 (0.53–1.02) 0.067
Composite vascular endpointb 50 56 0.75 (0.50–1.10) 0.139
CRP quartile 3: 45 and p12.4 mg/l, n=312
All-cause death 63 94 0.79 (0.57–1.11) 0.174
Composite vascular endpointb 52 78 0.79 (0.55–1.13) 0.203
CRP Quartile 4: 412.4 mg/l n=311
All-cause death 101 91 1.02 (0.77–1.37) 0.881
Composite vascular endpointb 62 57 1.06 (0.73–1.54) 0.750
CRP, C-reactive protein.
aExplanatory variables were selected by a stepwise process with adjustment for: gender, age, phosphate, hemoglobin, glycated hemoglobin, ever smoking, systolic and
diastolic blood pressure, body mass index, ultrafiltration volume, duration of dialysis, arteriovenous fistula, history of stroke or transitory ischemic attack, coronary artery
disease (history of myocardial infarction, coronary artery bypass grafting, percutaneous coronary intervention, and angiographically documented coronary artery disease),
history of peripheral vascular disease, and history of congestive heart failure (predominantly New York Heart Association class II).
bComposite vascular endpoint consists of myocardial infarction, cardiac death and stroke.
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In the cases of sudden death and stroke the mean of two
consecutive CRP measurements was of higher predictive
value than one baseline CRP alone. Whereas this study is the
first on CRP and sudden death in kidney patients and sparse
data exist in the general population,25,26 more work has been
performed with respect to stroke.27,28 In the general
population a clear association between one baseline CRP
measurement and outcome has been described whereas in
this study the baseline measurement alone slightly missed
statistical significance and a second measurement was
necessary to detect this association. Possible explanations
for this might be that the relationships between stroke,
sudden death, and CRP in hemodialysis patients are not as
strong as in the general population and, furthermore, that a
second measurement corrects for the intraindividual
change in CRP which might be of special importance in
dialysis patients who are exposed to multiple inflammatory
stimuli. Against this background, the present analysis adds
new evidence to current knowledge that serial measurement
of CRP may improve the prediction of sudden death and
stroke in patients with type 2 diabetes mellitus on
hemodialysis.
Although CRP is an established risk factor for cardiovas-
cular events, including myocardial infarction,29 we, like
several other investigators,15,30 did not find a clear association
between CRP (baseline, mean, and change from baseline) and
myocardial infarction. The latter could still be due to the
limited number of endpoints.
Our study has several limitations. It is a post hoc analysis
within a selected cohort of German patients with type 2
diabetes mellitus on hemodialysis treatment. Therefore, the
relationship between CRP and risk may not be generalizable
to other populations. Furthermore, causality cannot be
inferred from these associations.
In conclusion, CRP is useful in determining the risk of the
CVE and all-cause mortality and a second measurement
during longitudinal follow-up improves the prediction of
sudden death and stroke in patients with type 2 diabetes
mellitus on hemodialysis treatment. The association
between CRP and outcome was independent of clinical
information and further laboratory parameters. Thus, the
current data provide an improved method of identifying
persons at very high risk. In addition, CRP increased
significantly over time in placebo-treated patients and
atorvastatin showed antiinflammatory properties when
impeding this increase. However, this did not translate into
clinical benefit as atorvastatin therapy was not effective in
reducing the CVE or all-cause death in patients grouped
according to baseline CRP.
MATERIALS AND METHODS
Study design and participants
The design and methods of the 4D study have previously been
reported in detail.31 Briefly, the 4D study was a randomized,
multicenter trial including 1255 patients with type 2 diabetes
mellitus, 18–80 years of age, and a previous duration of maintenance
hemodialysis of less than 2 years. Between March 1998 and October
2002, patients were recruited in 178 dialysis units throughout
Germany. After a run-in period of 4 weeks, patients were randomly
assigned to receive double-blind treatment with either 20 mg of
atorvastatin once daily (n¼ 619) or placebo (n¼ 636). Data were
recorded at 4 weeks and every 6 months. At each follow-up a blood
sample was taken and information was recorded about any
suspected study endpoint or other serious adverse experience.
Further details related to study endpoints were sought from family
doctors, emergency physicians, hospitals, and local health authorities.
Outcome measures
Endpoints were evaluated by a specialized committee blinded to
study treatment based on prespecified criteria.8,31 The primary study
outcome was a composite of death from cardiac causes, myocardial
infarction, and stroke, whichever occurred first (CVE). Sudden
death, stroke, myocardial infarction, and death from any cause were
defined as secondary outcome measures. These five endpoints were
considered to be the outcome measures in this post hoc analysis.
Laboratory procedures
All laboratory measurements of the 4D study as well as the present
analysis of CRP were performed centrally at the Department of
Clinical Chemistry, University of Freiburg, Germany. Measurements
of CRP were performed by turbidimetry on a Modular PP analyzer
(Roche Diagnostics, Mannheim, Germany). Baseline and 6 months
serum samples from each individual were run in parallel. The
interassay coefficient of variance for CRP was below 5%. Blood
samples were taken before start of dialysis and administration of
heparin or further drugs and serum was kept at 80 1C until
analysis.
Statistical analysis
Patient data are presented according to quartiles of baseline CRP. P-
values for comparison between groups of baseline CRP quartiles
were derived from a general linear model for continuous variables
and a logistic regression analysis for categorical variables both
adjusted for age and gender, as appropriate.
The Wilcoxon’s signed-rank test was used to compare baseline
with post-baseline CRP within each treatment group and the
Wilcoxon’s rank-sum test was used to compare the atorvastatin with
the placebo group regarding CRP (baseline, post-baseline, and
change from baseline). Kaplan–Meier estimates for cumulative
incidences were calculated for all outcome measures. The Cox
proportional hazards regression model was used to estimate relative
risks and corresponding 95% CIs. First, the association of baseline
CRP with outcome was analyzed as continuous variable (logarith-
mically transformed, because values were not normally distributed),
and as categorical variable (quartiles of baseline CRP, with the first
quartile serving as reference). Second, the association between the
mean CRP value resulting of two consecutive measurements
(baseline and follow-up value) and outcome was analyzed accord-
ingly. Third, the change from baseline CRP and outcome was
evaluated as continuous variable (logarithmically transformed ratio
of post-baseline/baseline CRP) and as categorical variable (quartiles
of percent change in CRP with the first quartile serving as reference).
Finally, the effect of atorvastatin on the CVE and mortality was
analyzed in patients grouped according to quartiles of baseline CRP.
The following explanatory variables were considered for inclu-
sion into the different Cox proportional hazards regression models:
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Gender, age, atorvastatin treatment (only models 1 and 2),
phosphate, LDL, hemoglobin, glycated hemoglobin (HbA1c), ever
smoking, systolic and diastolic blood pressure, body mass index,
ultrafiltration volume, duration of dialysis, arteriovenous fistula,
history of stroke/transitory ischemic attack, coronary artery disease
(myocardial infarction, coronary artery bypass grafting, percuta-
neous coronary intervention, and angiographically documented
coronary artery disease), peripheral vascular disease, and congestive
heart failure (predominantly New York Heart Association class II). A
stepwise selection procedure was used to determine the variables
included in the final model, separately for each endpoint. This
procedure starts examining the variable with the largest adjusted w2-
statistic, and adds variables to the model if Pp0.25 and retains them
if Pp0.15 in the following steps. In the final analysis a P-value
p0.05 was considered to be significant (in an exploratory sense). All
P-values are reported two-sided. Analyses were performed using SAS
version 8.2.
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